ArticleOncology letters2021
Plasma plastin-3: A tumor marker in patients with non-small-cell lung cancer treated with nivolumab.
Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 8 citations in OpenAlex.
- Proteomic Profiling of Density-Gradient Fractions Reveals Candidate Cell Surface Markers in Subpopulations of StarfishInternational journal of molecular sciences · 2026Article
- Lectin-captured plasma microRNAs predict response and survival in patients with non-small cell lung cancer treated with nivolumab.Oncology letters · 2026Article
- LONP2 Enhances Cervical Cancer Growth and Metastatic Potential by Upregulating PLS3 and Activating PI3K/AKT Signaling.Cancer management and research · 2026Article
- Structural mechanism for bidirectional actin cross-linking by T-plastin.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Identification of Tumor-SuppressiveInternational journal of molecular sciences · 2022Article
- Article
- Plastin 3 in health and disease: a matter of balance.Cellular and molecular life sciences : CMLS · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plastin-3 (PLS3) is a circulating tumor cell marker associated with aggressive cancer phenotypes. The present study aimed to investigate the usability of plasma PLS3 concentration in assessing the diagnosis, prognosis and sensitivity to treatment in patients with non-small-cell lung cancer (NSCLC) treated with nivolumab. A total of 33 patients with recurrent or advanced NSCLC were treated with nivolumab, and 10 healthy volunteers were retrospectively enrolled. Plasma concentrations of PLS3 were determined by ELISA. Plasma PLS3 concentration in patients with NSCLC was significantly higher compared with that in healthy volunteers (median 7.64 ng/ml vs. 3.13 ng/ml, P<0.001). Univariate analysis indicated that PLS3 ≤5.43 ng/ml was a predictor of partial response. Patients with PLS3 >8.55 ng/ml exhibited a poorer prognosis compared with those in the PLS3 ≤8.55 ng/ml group. A high plasma PLS3 concentration was a predictor of poor overall survival. In conclusion, plasma PLS3 concentration was identified as a marker for the diagnosis, treatment sensitivity and prognosis in patients with NSCLC treated with nivolumab. Plasma PLS3 may be a clinically useful tumor marker in patients with NSCLC; future prospective studies may confirm these results and explore its use in other cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.